Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med Expects Approval of First Novel Cancer Drug in 2018

publication date: Mar 12, 2018

In an review its drug development progress, Hutchison China MediTech (Chi-Med) reported it expects China approval of its first novel drug in 2018 and that it also spent $88 million on novel drug R&D last year. During 2017, Chi-Med completed a Phase III trial of fruquintinib, its VEGFR inhibitor for colorectal cancer. It is awaiting CFDA approval of its Suzhou production facility as the last step of the process. All together, Chi-Med has eight candidates in clinical trials in 36 different indications. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.